Publicaciones en las que colabora con Josep Maria Llovet Bayer (13)

2023

  1. Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy

    Gut, Vol. 73, Núm. 3, pp. 496-508

2022

  1. Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3443-3451

2021

  1. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

    Gastroenterology, Vol. 161, Núm. 3, pp. 879-898

2020

  1. Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6350-6361

  2. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

    Journal of Hepatology, Vol. 73, Núm. 2, pp. 315-327

2019

  1. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials

    British Journal of Cancer, Vol. 121, Núm. 4, pp. 340-343

  2. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

    Gut, Vol. 68, Núm. 6, pp. 1065-1075

  3. New Drugs Effective in the Systemic Treatment of Hepatocellular Carcinoma

    Clinical Liver Disease, Vol. 14, Núm. 2, pp. 56-61

  4. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

    Journal of Hepatology, Vol. 70, Núm. 6, pp. 1262-1277

2018

  1. Molecular therapies and precision medicine for hepatocellular carcinoma

    Nature Reviews Clinical Oncology, Vol. 15, Núm. 10, pp. 599-616

2017

  1. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity

    Journal of Hepatology, Vol. 66, Núm. 5, pp. 952-961

  2. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1166-1172

  3. Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”

    Journal of Hepatology